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Abstract: Inhibition of thymidylate synthase (TS) is the primary mode of action for 5-fluorouracil
(5FU) chemotherapy. TS expression is modulated by a variable number of tandem repeats in the TS
enhancer region (TSER) located upstream of the TS gene (TYMS). Variability in the TSER has been
suggested to contribute to 5FU-induced adverse events. However, the precise genetic associations
remain largely undefined due to high polymorphism and ambiguity in defining genotypes. To assess
toxicity associations, we sequenced the TSER in 629 cancer patients treated with 5FU. Of the 13 alleles
identified, few could be unambiguously named using current TSER-nomenclature. We devised a
concise and unambiguous systematic naming approach for TSER-alleles that encompasses all known
variants. After applying this comprehensive naming system to our data, we demonstrated that the
number of upstream stimulatory factor (USF1-)binding sites in the TSER was significantly associated
with gastrointestinal toxicity in 5FU treatment.
Keywords: 5-fluorouracil; capecitabine; fluoropyrimidine; thymidylate synthase; thymidylate synthase
enhancer region; upstream stimulatory factor 1; adverse drug reactions
1. Introduction
As the only de novo source of thymidylate, thymidylate synthase (TS) has a major
role in DNA replication through catalyzing the conversion of deoxyuridine-monophosphate to
deoxythymidine-monophosphate (dTMP), a precursor of deoxythymidine-triphosphate. Thymidylate
synthase gene (TYMS) expression levels are low in resting phase cells and high in proliferating
cells [1]. Inhibition of TS in proliferating cells leads to severe DNA damage, eventually resulting
in cell death [2] and, thus, represents an enticing therapeutic target in cancer. The antimetabolite
5-fluorouracil (5FU) and its oral prodrug capecitabine (Cp) are among the most commonly used
chemotherapeutic agents for the treatment of solid carcinomas [3], systemically affecting proliferating
cells. Fluorodeoxyuridine-monophosphate, a metabolite of 5FU, forms a stable ternary complex
with TS and the co-factor 5,10-methylene tetrahydrofolate, resulting in inhibition of dTMP synthesis.
The subsequent imbalance of the nucleotide pool leads to DNA damage and apoptosis [2]. Although
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TS is the major target of 5FU, and its systemic inhibition leads to serious toxicity, no TYMS variants
have been shown to be clinically relevant predictive markers of 5FU toxicity.
TYMS is located on chromosome 18p11.32, has a length of ~16 kb, and consists of seven exons.
It does not contain typical eukaryotic promoter DNA motifs, such as a TATA or CAAT box. However,
other regulating motifs in its 5′-UTR have been identified [4]. A 28bp variable number of tandem
repeats (rs45445694) in the TYMS enhancer region (TSER) has been reported to affect transcription [5]
with two repeats being less efficient than three [6]. A vast majority of the population carries alleles with
either two or three repeats in this region [7]; however, individuals with as many as nine TSER-repeats
have been described [8,9]. Those repeats are commonly named according to the corresponding number
of repeats, e.g., TSER-2R or simply 2R for the two repeats, 3R for three, etc. [7,10,11]. This nomenclature
is referred to here as “repeat number” (RN-) nomenclature. Furthermore, a G > C SNP (rs2853542) at
position 12 of the second repeat of the triple repeat allele has been suggested to reduce transcription
by abolishing an upstream stimulatory factor (USF1)-binding site [12,13]. SNP status is commonly
depicted by listing the nucleotide directly following the repeat (e.g., 3RG or 3RC [8,14,15]). In addition,
a rare G > C SNP (rs183205964) has been described in the TSER-2R allele, carrying a G > C base change
at the 12th nucleotide of the first 28bp-repeat, which is commonly depicted as 2RG or 2RC [14,15].
This nomenclature, which also takes the SNP into account (e.g., 2RC, 3RG, etc.), is referred to herein
as “repeat number, binding site, SNP” (RNBS-) nomenclature. A functional study showed that the
2RC allele has the lowest transcriptional activity of all known TSER-alleles [16]. Studies of TYMS
and the TSER as potential markers for tumor progression, overall survival, and 5FU-induced toxicity
have yielded inconclusive and, often, conflicting results, likely due to varying considerations for
TSER-repeat number and SNP status, as well as ambiguity in allele definitions [6,12,15–25].
A recently published meta-analysis [10] reported that the polymorphism c.742-227G>A (rs2612091)
within the Enolase Superfamily Member 1 gene (ENOSF1) was associated with the development of
severe hand-foot syndrome (HFS) in 5FU/Cp-treated patients. The ENOSF1 and TYMS genes partially
overlap on chromosome 18 and are transcribed in opposite directions. In-vitro studies suggested that
ENOSF1 might regulate TYMS at the protein and RNA levels [26]. In addition to the polymorphism in
ENOSF1, the TSER-2R variant was also associated with an increased risk of HFS in the same study.
However, consistent with other studies, only 2R and 3R alleles were distinguished and considered
in analyses, and SNP status was not taken into account [7,11]. Therefore, for the present study,
we investigated the complex enhancer structure of TYMS in a large Caucasian cohort and assessed the
effect of genetic variation in this region on the development of 5FU-related toxicity.
The TSER was sequenced in 629 patients of primarily Caucasian ancestry that were treated with the
fluoropyrimidine-based chemotherapy containing either 5FU or Cp. In total, 13 unique TSER-sequence
variants were discovered. Using RN-and RNBS-nomenclature, we were not able to classify all detected
variants unambiguously. Therefore, we devised an improved naming strategy that permits systematic
classification of all discovered sequence variants in the TSER. Furthermore, associations between
the identified repeat structures and severe fluoropyrimidine-related toxicity were also investigated.
The focus of the present study was specifically on early-onset toxicities where the clinical relevance of
predictive genetic markers is likely to be highest.
2. Materials and Methods
2.1. Patient Samples
This study included 515 patients from a previously described cohort [27] and 114 additional
patients recruited between February 2013 and December 2014 at the same centers using the same
inclusion criteria. Except for nine subjects, all patients self-declared their ancestry as Caucasian. Of the
629 total patients, 614 were prospectively recruited and 15 were retrospective cases (toxicity grade 2–5).
All patients were treated with 5FU- or Cp-based chemotherapy (Table 1). Blood samples were collected
and adverse events for 13 hematologic, gastrointestinal, infection, and dermatologic categories were
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recorded during the first two chemotherapy cycles. Adverse events were classified according to the
Common Terminology Criteria for Adverse Events (CTCAE) v3.0 [28]. All subjects gave their informed
consent for inclusion before they participated in the study. The study was conducted in accordance
with the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of the
Cantons of Bern, Switzerland (131/07; 150/2015) and St. Gallen, Switzerland (09/104/2B).
Table 1. Clinical, demographic, and toxicity data. The cohort consisted of 629 participants. FOLFOX:
chemotherapy regimen based on a combination of LV, 5FU (5-fluorouracil), and oxaliplatin; FOLFIRI:
chemotherapy regimen based on a combination of LV, 5FU, and irinotecan; Cp: capecitabine; CPL:
cis-or carboplatin; D: docetaxel; E: epirubicin; LV: leucovorin.
Grade 3–5 Grade 0–2 Total
N % N % N
Total
Total cohort 106 17 523 83 629
Collection
Prospectively 92 15 522 85 614
Retrospectively 14 93 1 7 15
Sex
Female 55 22 192 78 247
Male 51 13 331 87 382
Ancestry
Caucasian 104 17 516 83 620
Arab 0 0 3 100 3
African 1 50 1 50 2
Asian 0 0 2 100 2
Unknown 1 50 1 50 2
Treatment
FOLFOX, FOLFIRI 22 10 192 90 214
5FU +/−LV 12 11 100 89 112
5FU, CPL +/−D,E 36 30 86 70 122
Other 5FU regimen 10 28 26 72 36
Cp 26 18 119 82 145
Toxicity category
Hematologic toxicity 58 9 571 91 629
Gastrointestinal toxicity 55 9 574 91 629
Infection 24 4 605 96 629
Dermatologic toxicity 15 2 614 98 629
2.2. PCR and Sequence Analysis
Genomic DNA was extracted from EDTA blood samples using the BioRobot EZ1 (Qiagen, Hilden,
Germany) and the EZ1 DNA blood 350 L Kit (Qiagen). PCR reactions were performed using the
GC-rich PCR System (Roche Applied Science, Basel, Switzerland) on GeneAmp 9700 Thermal Cyclers
(Applied Biosystems, Foster City, CA, USA). Detailed information for primers and PCR products are
shown in Figure 1A. PCR conditions consisted of a denaturation step of 3 min at 96 ◦C, followed
by 45 cycles of 30 s at 96 ◦C, 30 s at 60 ◦C and 45 s at 72 ◦C, and a final extension step of 10 min at
72 ◦C. In five patients the genotype could not be inferred unambiguously. Therefore, the amplification
products were separated by gel electrophoresis followed by a purification of the corresponding bands
with the QIAquick Gel Extraction Kit (Qiagen). The purified fragments were amplified again with
the GC-rich PCR System. Amplification products were sequenced using the Big Dye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI Prism 3130× L
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Forward and reverse sequence analysis,
including SNP calling and repeat structure detection, were performed using Sequencher 4.10.1 (Gene
Codes Corporation, Ann Arbor, MI, USA) with heterozygous base calling. Heterozygous genotypes
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were called using the IUPAC nucleotide ambiguity code provided by Sequencher, as each heterozygous
allele combination generates a specific nucleotide ambiguity code pattern.
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Figure 1. The reference and observed structures of the TYMS TSER-region. (A) The reference structure 
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the forward primer 5’-GTG-GCT-CCT-GCG-TTT-CCC-CC-3’ (position 657543; 200bp upstream of the 
start codon in the NC_000018.10 reference) and the reverse primer 5’-GCT-CCG-AGC-CGG-CCA-
CAG-GCA-TG-3’ (including the start codon at the 3’-end indicated in bold) (B) Shown here are five 
variants of the imperfect tandem repeats together with the length of each repeat that were observed 
in 1258 sequenced TYMS-promoter region alleles. The presence of the USF1-binding E-box is 
indicated as a box for each of the five repeats. (C) Shown here are the 13 different TSER-alleles 
observed in 629 sequenced patients with the corresponding new nomenclature. 
2.3. Statistical Analyses 
The cohort was tested for deviations from Hardy-Weinberg-Equilibrium (HWE) with respect to 
TSER using the Genepop package of R (v3.6.3) [29]. Differences in allele frequencies between 
populations were assessed using Fisher’s exact tests. Univariable and multivariable logistic 
regression analyses for the assessment of genetic associations of TSER-repeat number and of binding 
site number with 5FU toxicity (two toxicity groups: grade 0–2, 3–5) as well as the Fisher’s exact test 
were performed using the R package Stats [30]. Multivariable regression models were adjusted for 
sex, age, concomitant cis-or carboplatin (CPL) administration, and DPYD-risk variant carrier status. 
Co-administration of cis- or carboplatin was previously shown to be associated with increased early-
onset toxicity in this cohort, whereas no effect was observed for other concomitant chemotherapeutics 
(e.g., oxaliplatin, anthracyclines), or for 5FU versus capecitabine [27]. DPYD-risk variants were 
defined for this study as the minor alleles for rs3918290, rs67376798, rs55886062, and rs75017182, all 
Figure 1. The ref r nce and observed structures of -region. (A) The r f rence structure
of the TSER (NC_000018.10:657’ 04. 57’743) consists of three imperfect epeats. Upstream of the repeats,
an inv rted repeat is indicated in light and dark green. The region was PCR-amplified using the forward
primer 5′-GTG-GCT-CCT-GC -T T- CC- C-3′ (position 657543; 200bp upstream of the start c don in
the NC_000018.10 reference) and the reverse primer 5′-GCT-CCG-AGC-CGG-CCA-CAG- CA-TG-3′
(including the start codon at the 3′-end indicated in bold) (B) Shown here are five variants of the
imperfect tandem repeats together with the length of each repeat that were observed in 1258 sequenced
TYMS-promoter region alleles. The presence of the USF1-binding E-box is indicated as a box for each
of the five repeats. (C) Shown here are the 13 different TSER-alleles observed in 629 sequenced patients
with the corresponding new nomenclature.
2.3. Statis cal Analyse
The cohort was tested for s from Hardy-Weinberg-Equilibrium (HWE) with respect
to i t p ckage of ( .6.3) [29]. Differences in allele frequencies between
po ulations were assessed using Fisher’s exact tests. Univariable and multivariable logistic regression
analyses for the assessment of genetic associations of TSER-repeat number and of binding site number
with 5FU toxicity (two toxicity groups: grade 0–2, 3–5) as well as the Fisher’s exact test were performed
using the R package Stats [30]. Multivariable regression models were adjusted for sex, age, concomitant
cis-or carboplatin (CPL) administration, and DPYD-risk variant carrier status. Co-administration of
cis- or carboplatin was previously shown to be associated with increased early-onset toxicity in this
cohort, whereas no effect was observed for other concomitant chemotherapeutics (e.g., oxaliplatin,
anthracyclines), or for 5FU versus capecitabine [27]. DPYD-risk variants were defined for this
study as the minor alleles for rs3918290, rs67376798, rs55886062, and rs75017182, all of which have
been demonstrated to significantly increase risk for 5FU-induced toxicity [31]. Association tests
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between 5FU-toxicity and TSER-repeat numbers were performed using additive genetic models for the
TSER-repeat number variable; patients carrying alleles with more than three TSER-repeat elements
were excluded from these specific analyses. In all analyses, p-values < 0.05 were considered significant.
3. Results
3.1. Polymorphisms in the TSER
Sequencing analysis of the TSER, which encompassed the inverted repeat located upstream of
the variable number of tandem repeats through the ATG-initiation codon (Figure 1A), was performed
in 629 patients. Thirteen unique TSER-variants were identified among the 1258 sequenced alleles
(Table 2). All TSER-genotypes were found to be in HWE. No variation was detected in the upstream
inverted repeat region (NC_000018.10:657’604.657’645) or in the region between the TSER and the
ATG-initiation codon.
Several sequence variants within the TSER-repeats could not be distinguished by fragment-length
analyses. Therefore, those alleles could not be classified unambiguously according to the commonly
used RN-nomenclature of TSER-polymorphisms that is based on scoring the apparent number of tandem
repeats (Figure 1B, Table 2). Specifically, all TSER-alleles were composed of varying combinations
of five different variants of the imperfect tandem-repeat elements. Several combinations of these
variants could not be classified even with the more specific RNBS-nomenclature, and the unambiguous
classification of variant combinations using reference SNPs was not possible. Therefore, we devised
a new nomenclature to designate a 28bp-, a 34bp-, and a 32bp-variant of the repeat element using
combinations of the Greek letters α, β, and γ, respectively. Compared to the α-variant, the β-and
γ-variants are characterized by six and four additional bases, respectively, at the 3′-end of the repeat
element. Subscript numbers are used to differentiate different alleles within a repeat. Additionally,
the presence of a putative USF1-binding site within a repeat (created by the G allele at position 12 in
α- or β-repeats) is denoted with a superscript plus sign (Figure 1B). While USF1-binding site presence
would also be indicated by specific subscript numbers, the inclusion of the plus superscript notation
enables rapid assessment of the number of sites in a given allele.
It is noted that this nomenclature is highly extensible. Any newly identified repeat with a length
other than 28 bp, 32 bp, or 34 bp can be labelled with subsequent Greek letters. Similarly, the already
known repeat structures can be extended as new sequence variants are discovered by increasing the
subscript number. If the new variant contains a USF1-binding site, the plus superscript designation
would also apply.
For all TSER-alleles observed in this study, the most 3′-repeat element was a β- or γ-variant.
The β-elements almost exclusively contained a C at position 12 and were designated β1. In the majority
of TSER-alleles, the 3′-terminal β-element was preceded by one or multiple α-elements (Figure 1C).
However, rare TSER-alleles containing multiple β-elements were observed. One example of such a
multiple β-element-containing allele was also observed previously in a Japanese cohort [8], in which it
was referred to as 3Rc-ins. The sequence structure of this 3Rc-ins allele is consistent with a duplication
of the β1-repeat region, indicating that the haploid genotype would be denoted as α1β1β1. One allele
carrying a G at position 12 in the β-repeat and one allele with a deletion of CC at position 28 in the
β-repeat were observed. These variants were designated β2 and γ1, respectively. Besides the single
β2 and γ1 alleles, no alleles without a β1 repeat were observed in the remaining 1256 alleles. Seven
alleles with two repeats and no USF-binding site were observed. The new nomenclature allowed
us to depict the highly variable repeat patterns (Figure 1C) in a concise and unambiguous way that
simultaneously denotes the number of repeats, the type and the order of repeat elements, and the
presence of USF-binding sites (α1+ + β2+). For example, the allele previously named as 3RG consists
of two identical 28bp-repeats followed by a 34bp-repeat, which has a C instead of a G at position 12.
With the proposed nomenclature the 3RG-allele is designated α1+α1+β1 and consists of two α1+-and
one β1-subunits, indicating that the allele contains two potential USF1-binding sites
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Table 2. Frequencies of TSER (TYMS enhancer region)-polymorphisms. Each of the 13 alleles in our cohort (N = 629) plus one allele (α1+α1+α1+α2β1) only detected in
the Japanese cohort (N = 263) previously reported by Kim et al. [8] is listed using the “New”, the “repeat number”(RN-), and the “repeat number, binding site, SNP”
(RNBS-) nomenclature (columns 1, 2, and 3; *: allelic designations given by Kim et al. [8]; na: no name could be assigned using this nomenclature). For each allele,
the number (N) of USF1 (upstream stimulatory factor)-binding sites (column 4), the number (N) of alleles (column 5), and the allele frequency (f%) (column 6) within
the cohort is shown. For comparison, column 7 shows the frequency of the common alleles in a Japanese cohort. Column 8 lists the p-values from Fisher’s exact test for
population allele frequency differences between the study cohort and the population from Kim et al. [8].
New Nomenclature Repeat Number(RN-) Nomenclature
Repeat Number,
Binding Site,
SNP (RNBS-)
Nomenclature
USF1-Binding Sites N Allele N Allele f% Kim et al. f% p-Value
a1+b1 2R 2RG 1 561 44.6 12.4 <0.0001
a1+a2b1 3R 3RC 1 360 28.6 42.0 <0.0001
a1+a1+b1 3R 3RG 2 308 24.5 42.1 <0.0001
a1+b1b1 3R 3RC-ins * 1 12 1.0 0.2 ns
a2b1 2R 2RC 0 6 0.5 - -
a1+a1+a1+b1 4R na 3 4 0.3 - -
a1+b2 2R 2RG 2 1 0.1 - -
a1+a1+a2b1 4R 4RC * 2 1 0.1 0.2 ns
a1+a2a2b1 4R na 1 1 0.1 - -
a1+a1+a2a2b1 5R na 2 1 0.1 - -
a1+a2b1a2b1 5R na 1 1 0.1 - -
a1+γ1 2R 2RG 1 1 0.1 - -
b1b1 2R 2RC 0 1 0.1 - -
a1+a1+a1+a2b1 5R 5RC * 3 0 0.0 2.1 <0.0001
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Because different TSER-repeat numbers were observed in different ethnic groups [9,32], we compared
the polymorphism frequencies of our large cohort with a Japanese cohort [8] to assess ethnic differences
at the repeat-structure level. Indeed, we observed that frequencies of α1+β1, α1+α2β1 and α1+α1+β1
TSER-variants differed substantially between Caucasian and Japanese populations (Table 2), with α1+β1
being more frequent in Caucasians and α1+α2β1 and α1+α1+β1 being more frequent in the Japanese
population. Interestingly, the frequency of the G > C polymorphism containing α2-repeat as a second
repeat in alleles with three repeat elements was similar compared to the frequency of α1+ in this
position. This was true in both populations. Approximately half of the three-repeat element-alleles
contained α2 as the second repeat. The α1+α1+α1+α2β1-allele was only observed in the Japanese
cohort, whereas the similar α1+α1+α2α2β1-allele was only detected in the Caucasian cohort.
3.2. Distribution of the Number of USF1-Binding Sites Between Different TSER-Repeat Genotypes
The transcription factor USF1 has been shown to bind to the consensus recognition domains in the
TSER to activate TYMS transcription [13]. Therefore, for further correlative studies we also classified
the alleles based on the number of USF1-binding sites. The USF1-binding sites number in the most
commonly detected TSER-repeat genotypes was assessed (Figure 2). Patients homozygous for the
2R-genotype almost exclusively carried two USF1-binding sites. Three 2R/2R patients carried only
one USF1-binding site in the TSER; one patient carried three USF1-binding sites. In heterozygous
2R/3R-carriers, the most frequent number of binding sites was also two. Among patients with a
homozygous 3R-genotype, three binding sites were observed most frequently. In total, eight patients
carried alleles with more than three repeat elements and could therefore not be assigned to any of the
three genotype combinations (2R/2R, 2R/3R, 3R/3R). These participants carried between two and five
USF1-binding sites in TSERs.J. Pers. Med. 2020, 10, x FOR PEER REVIEW 7 of 12 
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Figure 2. Number of USF1-binding sites per TSER-repeat genotype. Patients were classified according
to the number of repeat elements. The number of USF1-binding sites per patient was subsequently
determined. Eight patients carried alleles with more than three repeat elements and could therefore not
be assigned to a 2R-3R genotype.
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3.3. Association Analyses of TYMS TSER-Variants with Severe 5FU Toxicity
The association of the TSER-repeat polymorphisms with toxicity was assessed using univariable
and multivariable logistic regression analyses with two different models of allele classification. Model I
was based on the number of USF-binding sites per patient extracted from the new nomenclature and
which allowed the inclusion of all TSER-genotypes. Model II was based on RN-nomenclature and
excluded patients carrying alleles with more than three repeat elements.
In the univariable analysis, the number of USF1-binding sites was associated with the risk of
developing early-onset gastrointestinal toxicity (OR 1.66, p = 0.043; Table 3). After adjustment for sex,
age, carboplatin treatment, and DPYD-risk variant carrier status, the risk of severe gastrointestinal
toxicity remained significantly higher in patients with fewer USF1-binding sites in TSER (OR 1.74,
p = 0.034). The association between gastrointestinal toxicity and the number of USF1-binding sites was
also significant in a subgroup analysis containing only patients with 2R and 3R genotypes (n = 621; data
not shown). As shown in Figure 3A, the frequency of gastrointestinal toxicity decreased gradually from
20% in patients carrying one USF1-binding site to 0% in patients with five binding sites. Associations
did not reach significance when assessing other toxicity classes or overall toxicity.
Table 3. Toxicity association with number of USF1-binding sites. Associations were assessed in the
full cohort (n = 629). p-values from logistic regression models; 1 adjusted for cis-and carboplatin
co-administration, sex, age, and DPYD-risk variants. Significant p-values are shown in bold.
Univariable Multivariable 1
Outcome OR 95% CI p-Value OR 95% CI p-Value
Overall toxicity 1.04 0.76–1.46 0.793 1.08 0.77–1.54 0.670
Hematologic toxicity 0.73 0.49–1.10 0.122 0.73 0.48–1.13 0.148
Gastrointestinal toxicity 1.66 1.04–2.77 0.043 1.74 1.06–2.99 0.034
Infection 1.1 0.59–2.20 0.769 1.14 0.57–2.43 0.723
Dermatologic toxicity 1.29 0.58–3.27 0.558 1.28 0.57–3.25 0.576
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Figure 3. Frequency of severe gastrointestinal toxicity according to number of USF1-binding sites
and TSER-repeat genotypes. Gastrointestinal toxicity frequencies were stratified according to (A) the
number of USF1-binding sites in the full cohort of 629 patients and (B) TSER-repeat genotype in a
subcoh rt of 607 patients carrying only 2R or l r is s.
The number of S -repeats alone (i.e., in analyses that did not evaluate the number of
USF1-bi ding sites) was not significantly associated with gastroi testinal toxicity (univariable: OR 1.28,
p = 0.424; multivariable: OR 1.21, p = 0.348; Table 4). How ver, the frequency of s vere gastrointestinal
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toxicity was higher in homozygous 2R patients compared to the other two genotypes (Figure 3B),
consistent with the lower number of USF1-bindings sites in these patients. Of 182 patients homozygous
for 3R, 9.3% experienced toxicity grade ≥3 vs. 12.7% of 126 patients homozygous for 2R. Other toxicities
were also not associated with the number of TSER-repeats in univariable or multivariable analyses.
Table 4. Toxicity association with number of TSER-repeats. Associations were assessed in the 621 patients
carrying only two or three repeat-element alleles. p-values from logistic regression models; 1 adjusted for
cis-and carboplatin co-administration, sex, age, and DPYD-risk variants.
Univariable Multivariable 1
Outcome OR 95% CI p-Value OR 95% CI p-Value
Overall toxicity 0.96 0.71–1.30 0.814 0.98 0.71–1.34 0.887
Hematological toxicity 0.73 0.49–1.08 0.119 0.75 0.49–1.13 0.174
Gastrointestinal toxicity 1.18 0.79–1.75 0.424 1.21 0.81–1.82 0.348
Infection 0.93 0.51–1.66 0.803 1.06 0.58–1.93 0.845
Dermatological toxicity 1.05 0.50–2.19 0.895 0.97 0.45–2.04 0.929
4. Discussion
In the present study, we performed a sequence-based analysis of the TSER-region in a cohort of
629 5FU-treated patients that self-declared as “Caucasian”. Thirteen unique TSER-sequence variants
were observed (Table 2), of which not all could be assigned unambiguous genotypes using the current
RN or RNBS nomenclatures. Based on available information, we hypothesized that the number of
intact USF1-binding sites, which is dependent upon both the number of repeats and the variant status
within each repeat, is a contributor to 5FU toxicity risk. To address this hypothesis, we developed a
novel approach to assigning allele designations in the TSER that incorporates this information. These
genotypes were then assessed in correlative studies. We demonstrated that this improved naming
system can unambiguously assign allele names to all known TSER-sequences. Using this information,
we subsequently demonstrated that the number of USF1-binding sites within the TSER, not the repeat
status itself, was significantly associated with gastrointestinal toxicity in 5FU/Cp treatment.
The RN-nomenclature was previously introduced to classify TSER-fragment-length polymorphisms
by gel-electrophoresis [12]. Later studies added HaeIII digestion to detect the G > C SNP at position
12 of the repeats, giving rise to RNBS-nomenclature [19]. Neither naming system can accommodate
sequence-level information. The novel nomenclature system introduced herein overcomes those
limitations by distinguishing 28, 34, and 32 base pair repeat motifs as α, β, and γ, respectively, and by
designating sequence variants within each repeat using subscript numbers (Figure 1B). Using this new
method, all previously reported [8,33] repeat combinations, their structural order, and variant status
can be designated in a concise and unambiguous manner.
USF1 is a transcription factor that usually binds symmetrical E-box sequences (5′-CACGTG-3′) and
for TYMS TSER, it was shown that the factor can also bind to the sequence 5′-CACTTG-3′ [13]. With the
TSER, the number of USF1-binding sites varies depending on the number of repeat sequences (Figure 2)
and the genotype (G/C) at position 12 in the repeat, with the C allele abolishing the consensus-binding
site. The TSER-nomenclature we present in this manuscript clearly denotes the presence of a
USF1-binding site within each repeat, overcoming another limitation of RN/RNBS-nomenclature.
For example, a 4R-allele has been previously reported [9], the repeat-motif composition of which is not
overtly clear using the RN-nomenclature. In the present study, we observed three alleles (α1+α1+α1+β1,
α1
+α1
+α2β1, α1+α2α2β1) that would be classified as 4R; however, the number of USF1-binding sites,
as well as the SNP composition, varies in each.
The number of USF1-binding sites per patient in our cohort varied between one and five. Our
data demonstrate a significant inverse correlation between gastrointestinal toxicity and the number of
TSER USF1-binding sites. This finding is consistent with another recent study that found ≤1 TSER
USF1-binding site per patient to be associated with an increased risk of overall severe toxicity to
5FU [15]. In that study, gastrointestinal toxicity was also more common in patients with ≤1 binding site;
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however, statistical significance was not achieved [15]. Another study reported a similar non-significant
trend for this apparent protective effect against 5FU-induced toxicity [34]. These observations can
be explained by increased TYMS transcriptional activity in patients with more USF1-binding sites.
It is noted that in a small cohort of 29 colorectal cancer patients, transcriptional activity was not
shown to be conclusively associated with the number of USF1-binding sites [16]. Therefore, additional
adequately powered in vivo and in vitro studies are needed to precisely define the role of USF1-driven
transcription of TYMS in 5FU toxicity.
Notable differences in TSER-genotype frequencies have been reported for populations with
different racial/ethnic compositions, providing further impetus for a robust naming system that can
accommodate diverse genotypes. Whereas our cohort displayed similar TSER-repeat frequencies as in
other large Caucasian cohorts [34,35], the frequencies ofα1+β1,α1+α2β1 α1+α1+β1, andα1+α1+α1+α2β1
differed substantially from a previously reported Japanese population [8]. Eight TSER-variants were
identified in our cohort that were not present in the Japanese cohort (Table 2). Further comparisons
with other ethnic groups could provide additional insight into toxicity risk predictors; however,
other studies, including a study of African individuals [9], only reported the number of repeats, limiting
potential analyses. As a first application of the proposed nomenclature, our results highlight the
importance of considering USF1-binding sites, as the analysis based on the RN-nomenclature failed to
identify a toxicity association.
Several large meta-analyses [7,10,11] have reported that either the 2R/2R-genotype or the 2R-allele
were associated with a higher toxicity risk. In a cohort of Cp-treated patients, 2R-carriers were
predominantly associated with increased risk for diarrhea [7]. In partial agreement with this finding,
our study found higher levels of severe gastrointestinal toxicity in homozygous 2R-allele carriers;
however, this finding was not statistically significant. Collectively, the correlations between toxicity and
2R that have been reported by previous studies remains consistent with our results because 2R-repeats
are more likely to carry a reduced number of USF1-binding sites compared to larger repeat expansions
(e.g., 3R; Figure 2). Our data suggest that expanded considerations that encompass USF1-binding sites
may offer greater predictive value.
One limitation to our study was that the cohort was not large enough to fully investigate rare
TSER-variants for toxicity associations. Anecdotal evidence suggests that 5FU-treated patients with
rare TSER-genotype combinations, for example without any USF1-binding site, might have a strongly
increased risk of severe adverse events [15]. However, the limited sample size in the present report
was inadequate to address this question; future expanded studies are planned where we can fully
utilize all information encoded by the new nomenclature. In contrast to Hamzic et al. [10], we did
not observe an association between the 2R-allele and HFS. Notably, our cohort consisted mainly of
5FU-treated patients, and HFS is considered an adverse event specific to Cp, not 5FU [36]. The limited
number of Cp-treated patients, coupled with the low overall occurrence of severe HFS in our cohort,
provided inadequate statistical power to assess this association. An additional trial conducted in North
America did not find TSER-repeat number to be associated with toxicity [18]. While the exact reason
for this discrepancy with our results cannot be inferred, the focus on irinotecan-based therapies in that
trial and the masking effects of uninvestigated DPYD-risk variants may have contributed.
5. Conclusions
In conclusion, we propose a simple nomenclature for TSER-alleles that encodes multiple levels of
information pertaining to repeats, variants, and USF1-binding sites. This concise and unambiguous
naming system can accommodate rare and novel sequence variants and, therefore, enables expanded
analyses of TSER in association studies. After applying this comprehensive naming system to
sequencing data gathered in a Caucasian cohort encompassing 629 5FU-treated cancer patients,
we demonstrated that the number of upstream stimulatory factor (USF1-)binding sites in the TSER
was significantly associated with gastrointestinal toxicity in 5FU treatment.
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